BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys Announces Allowance of DPX-Related Patent for Japan
BioVaxys Technology Corp. has executed a non-binding Letter of Intent (LoI) to acquire the core platform technology and entire immunotherapeutics intellectual property portfolio of discovery, preclinical development, and Phase II clinical study stage assets in oncology and other immunological fields, including active licenses with several pharma companies, formerly owned by an unnamed biotechnology company and now held by the unnamed company's former secured creditor.